These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 37543612)

  • 1. Natural killer cell-derived exosomes for cancer immunotherapy: innovative therapeutics art.
    Hatami Z; Hashemi ZS; Eftekhary M; Amiri A; Karpisheh V; Nasrollahi K; Jafari R
    Cancer Cell Int; 2023 Aug; 23(1):157. PubMed ID: 37543612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma.
    Zhu L; Kalimuthu S; Gangadaran P; Oh JM; Lee HW; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Theranostics; 2017; 7(10):2732-2745. PubMed ID: 28819459
    [No Abstract]   [Full Text] [Related]  

  • 3. Delivery of human natural killer cell-derived exosomes for liver cancer therapy: an in vivo study in subcutaneous and orthotopic animal models.
    Kim HY; Min HK; Song HW; Yoo A; Lee S; Kim KP; Park JO; Choi YH; Choi E
    Drug Deliv; 2022 Dec; 29(1):2897-2911. PubMed ID: 36068970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
    Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Front Immunol; 2018; 9():824. PubMed ID: 29740437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
    Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
    J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
    Ruppel KE; Fricke S; Köhl U; Schmiedel D
    Front Immunol; 2022; 13():822298. PubMed ID: 35371071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells.
    Zhu L; Gangadaran P; Kalimuthu S; Oh JM; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S166-S179. PubMed ID: 30092165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy.
    Fabian KP; Hodge JW
    Mol Ther Oncolytics; 2021 Dec; 23():266-276. PubMed ID: 34761106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
    Wang X; Yang X; Yuan X; Wang W; Wang Y
    Exp Hematol Oncol; 2022 Nov; 11(1):85. PubMed ID: 36324149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia enhances the production and antitumor effect of exosomes derived from natural killer cells.
    Jiang Y; Jiang H; Wang K; Liu C; Man X; Fu Q
    Ann Transl Med; 2021 Mar; 9(6):473. PubMed ID: 33850870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.
    Zhang C; Hu Y; Xiao W; Tian Z
    Cell Mol Immunol; 2021 Sep; 18(9):2083-2100. PubMed ID: 34267335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.